17.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.15
Aprire:
$17.06
Volume 24 ore:
1.82M
Relative Volume:
0.92
Capitalizzazione di mercato:
$1.21B
Reddito:
$1.03B
Utile/perdita netta:
$-94.55M
Rapporto P/E:
-12.44
EPS:
-1.4012
Flusso di cassa netto:
$-3.64M
1 W Prestazione:
+7.33%
1M Prestazione:
+6.41%
6M Prestazione:
-15.72%
1 anno Prestazione:
+18.89%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care Inc
|
17.43 | 1.21B | 1.03B | -94.55M | -3.64M | -1.4012 |
|
ABT
Abbott Laboratories
|
103.70 | 179.44B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
95.41 | 122.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
307.15 | 117.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
45.69 | 66.22B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
89.07 | 51.34B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-07 | Iniziato | Barclays | Equal Weight |
| 2026-09-30 | Reiterato | Citigroup | Neutral |
| 2026-08-21 | Iniziato | William Blair | Outperform |
| 2026-07-28 | Ripresa | UBS | Neutral |
| 2026-06-23 | Iniziato | Deutsche Bank | Hold |
| 2026-06-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-05-12 | Iniziato | The Benchmark Company | Hold |
| 2026-03-19 | Aggiornamento | Truist | Hold → Buy |
| 2026-03-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Aggiornamento | Lake Street | Hold → Buy |
| 2026-02-20 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Buy |
| 2025-12-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Form 4 Tandem Diabetes Care Inc: Jean-Claude Kyrillos (EVP & Chief Operating Officer) For: 15 October - Investing.com Nigeria
After a COO stock conversion, Tandem Diabetes Care (TNDM) withheld 1,926 shares for taxes; none were sold. - Stock Titan
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo! Finance Canada
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care Q2 2026 Earnings Call Transcript - Benzinga
App Recall Might Change The Case For Investing In Tandem Diabetes Care (TNDM) - Simply Wall Street
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance Singapore
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - TradingView
Barclays Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $18 - Moomoo
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care, Inc. (0M0F.L) stock price, news, quote and history - Yahoo Finance Australia
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire
Tandem Diabetes Care (NasdaqGM:TNDM) Stock Forecast & Analyst Predictions - Simply Wall Street
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System - Yahoo Finance
Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Operating cash flow per share of Tandem Diabetes Care, Inc. – HAN:TD5A - tradingview.com
Tandem Diabetes Care, Inc. (0M0F.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tandem Diabetes (TNDM) Expands Mobi Insulin Delivery System to 1 - GuruFocus
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - Moomoo
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - Yahoo Finance
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - News-Press NOW
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Yahoo Finance
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Business Wire
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Nasdaq
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo! Finance Canada
A Look at Tandem Diabetes Care Inc (TNDM) After 3.3% Gain -- GF Value $24.10 vs Price $15.72 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating - marketscreener.com
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating - Yahoo Finance
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - finance.yahoo.com
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know - Yahoo Finance
A Look at Tandem Diabetes Care Inc (TNDM) After 6.4% Decline -- GF Value $24.09 vs Price $16.38 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Exploring a 62.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Tandem Diabetes Care, Inc. (TNDM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return? - Yahoo Finance
Officer at Tandem Diabetes Care (NASDAQ: TNDM) plans 360-share stock sale - Stock Titan
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? - Yahoo Finance
A Look at Tandem Diabetes Care Inc (TNDM) After 7.7% Gain -- GF Value $24.08 vs Price $17.54 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
(TNDM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tandem Diabetes Care: Stop Paying For Tomorrow's ProfitsStrong Sell (NASDAQ:TNDM) - Seeking Alpha
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
Zacks Investment Research - גלובס
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tandem Diabetes Care Inc Azioni (TNDM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MARK NOVARA | Officer |
Sep 17 '26 |
Proposed Sale |
17.53 |
360 |
6,311 |
0 |
| MARK NOVARA | Officer |
Aug 18 '26 |
Proposed Sale |
22.26 |
131 |
2,915 |
0 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
3,014 |
0 |
2,425 |
| Carpenter Rick | EVP & Chief Technology Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
2,507 |
0 |
32,968 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
3,014 |
0 |
32,626 |
| Sheridan John F | PRESIDENT & CEO |
Aug 15 '26 |
Option Exercise |
0.00 |
15,916 |
0 |
165,315 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
1,010 |
0 |
30,825 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 15 '26 |
Option Exercise |
0.00 |
4,120 |
0 |
52,982 |
| Morrison Susan | EVP & Chief Admin. Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
2,827 |
0 |
53,283 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
3,636 |
0 |
31,741 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):